TIME

How a discontinued Alzheimer’s drug study got a second life

“MY FIRST REACTION WAS TO BE ANGRY,” SAYS JOANN Wooding. “I’ve gotten over that, and is more the word right now.” Wooding’s husband Peter, who was diagnosed with Alzheimer’s in 2016, was among the more than 3,200 people with the disease who volunteered to test a promising drug called aducanumab. In earlier study results released the same year, the drug, developed by Biogen, a U.S. biotech company, and Eisai, a Japanese pharmaceutical manufacturer, seemed to accomplish a number of firsts for people with Alzheimer’s. It appeared to shrink deposits of the protein amyloid accumulating in the brains of patients and, perhaps more important, also slow the cognitive decline

Citiți o mostră, înregistrați-vă pentru a citi în continuare.

Mai multe de la TIME

TIME2 min citite
Against GDP
THIS YEAR, NEW ZEALAND BECAME THE FIRST NATION TO formally drop gross domestic product (GDP) as its main measure of economic success. The government of Prime Minister Jacinda Ardern said the budget would aim not at maximizing GDP but instead at maxim
TIME2 min citite
Reclaiming The West
THE COWBOY HAS LONG BEEN one of America’s most potent symbols. Strivers have taken inspiration from rugged frontier warriors who embodied American individualism, creativity and the quest for manifest destiny. For the most part, these icons have been
TIME3 min citite
A Better Way To Teach Kids About Thanksgiving
IF YOU LEARNED ABOUT THANKSGIVING IN AN AMERICAN elementary school, chances are you learned that the holiday commemorates how the Pilgrims of Plymouth, Mass., fresh off the Mayflower, celebrated the harvest by enjoying a potluck-style dinner with the